Australia appears to be welcome a groundbreaking therapy for excess weight: Retatrutide. The dual molecule – working on both GLP-1 and GIP receptors – shows promising efficacy in clinical studies, suggesting substantial reductions in BMI. While availability remains with the Therapeutic Goods Administration (TGA), a number of Australians battlin